Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28545888
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Adv+Drug+Deliv+Rev
2017 ; 114
(ä): 79-101
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Delivering safer immunotherapies for cancer
#MMPMID28545888
Milling L
; Zhang Y
; Irvine DJ
Adv Drug Deliv Rev
2017[May]; 114
(ä): 79-101
PMID28545888
show ga
Cancer immunotherapy is now a powerful clinical reality, with a steady
progression of new drug approvals and a massive pipeline of additional treatments
in clinical and preclinical development. However, modulation of the immune system
can be a double-edged sword: Drugs that activate immune effectors are prone to
serious non-specific systemic inflammation and autoimmune side effects. Drug
delivery technologies have an important role to play in harnessing the power of
immune therapeutics while avoiding on-target/off-tumor toxicities. Here we review
mechanisms of toxicity for clinically-relevant immunotherapeutics, and discuss
approaches based in drug delivery technology to enhance the safety and potency of
these treatments. These include strategies to merge drug delivery with adoptive
cellular therapies, targeting immunotherapies to tumors or select immune cells,
and localizing therapeutics intratumorally. Rational design employing lessons
learned from the drug delivery and nanomedicine fields has the potential to
facilitate immunotherapy reaching its full potential.
free
free
free
